Clinical Trials
14 trialsNCT04786964 2025-04-02
CONTERNO
Checkpoint Therapeutics, Inc.
Phase 3 Terminated
NCT02578680 2024-09-20
MK-3475-189
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03950674 2024-06-10
MK-3475-189
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00998946 2021-11-05
Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Spectrum Pharmaceuticals, Inc
Phase 2 Completed
NCT00606502 2021-03-05
Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment
Spectrum Pharmaceuticals, Inc
Phase 2 Completed
NCT00481871 2020-01-07
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies
Acrotech Biopharma Inc.
Phase 1/2 Completed
NCT01118624 2020-01-07
Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer
Acrotech Biopharma Inc.
Phase 2 Completed
NCT00722553 2019-12-17
Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder
Acrotech Biopharma Inc.
Phase 2 Completed
NCT03349333 2019-10-01
A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL
Mundipharma (China) Pharmaceutical Co. Ltd
Phase 3 Completed
NCT01165021 2019-09-25
A Study of Pemetrexed/Cisplatin as Pre-operative Treatment of Early Stage Nonsquamous Non-Small Cell Lung Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00806819 2017-02-02
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Boehringer Ingelheim
Phase 3 Completed
NCT01283971 2014-02-10
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor
Hoffmann-La Roche
Phase 4 Terminated
NCT01057589 2013-09-18
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00609518 2010-12-28
A Study for Patients With Non-Squamous Non-Small Cell Lung Cancer
Eli Lilly and Company
Phase 2 Completed